A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease

Marín, Rafael; Ruilope, Luís M.; Aljama, Pedro; Aranda, Pedro J.; Segura, Julián; Díez, Javier

doi:10.1097/00004872-200110000-00023

Cited by 83 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the patients receiving an ACE inhibitor showed lower SBP values; thus, the better BP control in the fosinopril arm could have resulted in a better outcome. [100] On the other hand, the J-MIND study showed no differences between enalapril and nifedipine retard with respect to progression from normoalbuminuria to microalbuminuria and from microalbuminuria to overt proteinuria. The incidence of this outcome was similar in both groups.…”

Section: Dihydropyridine Calcium Antagonistsmentioning

confidence: 91%

Calcium Antagonists and Renal Failure Progression

Robles

2008

Renal Failure

View full text Add to dashboard Cite

Although tighter blood pressure control is considered the main mechanism for preventing the progression of chronic renal failure, angiotensin-converting enzyme inhibitors and angiotensin receptors blockers seem to have an additional organ protective role. The effects of calcium antagonists in renal disease are not so clearly defined. Calcium antagonists have pleiotropic effects that might contribute to protect the kidney, such as attenuating mesangial entrapment of macromolecules, countervailing the mitogenic effect of platelet-derived growth factors and platelet-activating factors, and suppressing mesangial cell proliferation. They could also act as free radical scavengers and inhibit the renal effects of endothelin. Some evidence has been accumulated demonstrating that certain new dihydropyridinic calcium antagonists may affect postglomerular as well as preglomerular vessels, resulting in decreased filtration fraction and nephroprotective effect as renin-angiotensin axis-blocking drugs. Though there are few reports on the clinical renal effects of new calcium antagonists, they have rendered promising results. Manidipine does not increase proteinuria as do some classic calcium antagonists, and lercanidipine combined with renin-angiotesin axisblocking drugs reduce proteinuria. Both drugs have been shown to decrease microalbuminuria when administered alone.

show abstract

Section: Dihydropyridine Calcium Antagonistsmentioning

confidence: 91%

Calcium Antagonists and Renal Failure Progression

Robles

2008

Renal Failure

View full text Add to dashboard Cite

show abstract

“…Частота виявлення МС за відповідними крите-ріями в популяції дорослих -25-40 % населення [2,3,39]. В індустріально розвинених країнах серед населення віком понад 30 років поширеність МС N¹ 6 (56), 2017 КЛІНІЧНІ ДОСЛІДЖЕННЯ / CLINICIAL RESEARCHES становить 10-20 % [39].…”

Section: вступunclassified

“…В індустріально розвинених країнах серед населення віком понад 30 років поширеність МС N¹ 6 (56), 2017 КЛІНІЧНІ ДОСЛІДЖЕННЯ / CLINICIAL RESEARCHES становить 10-20 % [39]. МС частіше зустрічається в чоловіків, у жінок його частота зростає в постме-нопаузальному періоді [2, 46,61].…”

Section: вступunclassified

“…Серцево-судинні захворювання (ССЗ) є безпо-середньою причиною смерті у 65-75 % хворих на ЦД 2-го типу [4, 39,40]. Сьогодні не викликає сум-нівів, що МС є одним з основних факторів ризику розвитку ССЗ: інсульту, ІХС, інфаркту міокарда (ІМ), серцевої недостатності (СН) [39,40,48,50,51].…”

Section: вступunclassified

“…Сьогодні не викликає сум-нівів, що МС є одним з основних факторів ризику розвитку ССЗ: інсульту, ІХС, інфаркту міокарда (ІМ), серцевої недостатності (СН) [39,40,48,50,51]. Збільшення рівня глюкози натще на 10 % у віці 50 років асоціюється зі збільшенням ризику ІМ на 21,7 % після 60 років [39,40].…”

Section: вступunclassified

See 2 more Smart Citations

Вплив Різних Класів Антигіпертензивних Препаратів На Інсулінорезистентність У Пацієнтів Із М’якою Та Помірною Артеріальною Гіпертензією

Rekovets

Sіrenko

Savitsky

et al. 2022

View full text Add to dashboard Cite

show abstract

Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE It is uncertain whether and when angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) treatment should be discontinued in individuals with low estimated glomerular filtration rate (eGFR).OBJECTIVE To investigate the association of ACE-I or ARB therapy discontinuation after eGFR decreases to below 30 mL/min/1.73 m 2 with the risk of mortality, major adverse cardiovascular events (MACE), and end-stage kidney disease (ESKD). DESIGN, SETTING, AND PARTICIPANTSThis retrospective, propensity score-matched cohort study included 3909 patients from an integrated health care system that served rural areas of central and northeastern Pennsylvania. Patients who initiated ACE-I or ARB therapy from January 1, 2004, to December 31, 2018, and had an eGFR decrease to below 30 mL/min/1.73 m 2 during therapy were enrolled, with follow-up until January 25, 2019.EXPOSURES Individuals were classified based on whether they discontinued ACE-I or ARB therapy within 6 months after an eGFR decrease to below 30 mL/min/1.73 m 2 . MAIN OUTCOMES AND MEASURESThe association between ACE-I or ARB therapy discontinuation and mortality during the subsequent 5 years was assessed using multivariable Cox proportional hazards regression models, adjusting for patient characteristics at the time of the eGFR decrease in a propensity score-matched sample. Secondary outcomes included MACE and ESKD. RESULTSOf the 3909 individuals receiving ACE-I or ARB treatment who experienced an eGFR decrease to below 30 mL/min/1.73 m 2 (2406 [61.6%] female; mean [SD] age, 73.7 [12.6] years), 1235 discontinued ACE-I or ARB therapy within 6 months after the eGFR decrease and 2674 did not discontinue therapy. A total of 434 patients (35.1%) who discontinued ACE-I or ARB therapy and 786 (29.4%) who did not discontinue therapy died during a median follow-up of 2.9 years (interquartile range, 1.3-5.0 years). In the propensity score-matched sample of 2410 individuals, ACE-I or ARB therapy discontinuation was associated with a higher risk of mortality (hazard ratio [HR], 1.39; 95% CI, 1.20-1.60]) and MACE (HR, 1.37; 95% CI, 1.20-1.56), but no statistically significant difference in the risk of ESKD was found (HR, 1.19; 95% CI, 0.86-1.65). CONCLUSIONS AND RELEVANCEThe findings suggest that continuing ACE-I or ARB therapy in patients with declining kidney function may be associated with cardiovascular benefit without excessive harm of ESKD.

show abstract

A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease

Cited by 83 publications

References 23 publications

Calcium Antagonists and Renal Failure Progression

Calcium Antagonists and Renal Failure Progression

Вплив Різних Класів Антигіпертензивних Препаратів На Інсулінорезистентність У Пацієнтів Із М’якою Та Помірною Артеріальною Гіпертензією

Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate

Contact Info

Product

Resources

About